

the capabilities of the expression system. Synthesis of 'native' full-size enzyme (92 kDa) will have highest priority. Alternatively, a truncated TG1 with high activity and stability may be tested (65 kDa). A standard transglutaminase activity assay will be used by the contractor to determine TG1 activity, and assess stability and optimal storage conditions.

This CRADA aims include the rapid development of a supply of active human Transglutaminase I enzyme for further characterization and research, publication of research results and possible exploitation of commercial opportunities. The CRADA partner(s) will enjoy rights of first negotiation for licensing Government rights to any inventions arising under the agreement.

The role of the NIAMS in this CRADA will be as follows:

- (1) Provide the Collaborator(s) with samples of the clone gene DNA;
- (2) Perform initial tests on Collaborator produced test enzyme for activity and function; and
- (3) Provide expertise in optimizing commercial development of this compound to produce the most useful product.

The role of the Collaborator will be as follows:

- (1) Produce high quality Transglutaminase I in sufficient quantities for research studies;
- (2) Perform initial testing of Transglutaminase I for purity; and
- (3) Develop method(s) to produce large quantities of Transglutaminase I for commercial distribution.

Selection criteria for choosing the CRADA partner(s) will include but not be limited to:

- (1) Ability to produce high quality Transglutaminase I in large quantities for research and evaluation;
- (2) The level of financial support the Collaborator will supply for the CRADA related Government activities;
- (3) A willingness to cooperate with the NIAMS in the publication of research results;
- (4) An agreement to be bound by DHHS rules involving human subjects, patent rights, and ethical treatment of animals; and
- (5) Agreement with provisions for equitable distribution of patent rights to any inventions developed under the CRADA(s).

Generally, the rights of ownership are retained by the organization which is the employer of the inventor with, (1) an irrevocable, non-exclusive, royalty-free license to the Government (when a company employee is sole inventor) or (2) an option to negotiate an exclusive or non-exclusive license to the company

on terms that are appropriate (when the Government employee is the sole inventor).

Dated: March 4, 1997.  
Sheila E. Merritt,  
*Executive Officer, NHLBI.*  
[FR Doc. 97-6634 Filed 3-14-97; 8:45 am]  
BILLING CODE 4140-01-M

### National Heart, Lung, and Blood Institute; Notice of Closed Meetings

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following Heart, Lung, and Blood Special Emphasis Panel (SEP) meetings.

*Name of SEP:* Modeling DNA Diversity in Cardiovascular Health/Disease.

*Date:* March 26-27, 1997.

*Time:* 7:30 p.m.

*Place:* Holiday Inn, Gaithersburg, #2 Montgomery Village Avenue, Gaithersburg, Maryland 20879.

*Contact Person:* Anthony M. Coelho, Jr., Ph.D., Two Rockledge Center, Room 7194, 6701 Rockledge Drive, Bethesda, MD 20892-7924, (301) 435-0299.

*Purpose/Agenda:* To review and evaluate grant applications.

This notice is being published less than fifteen days prior to this meeting due to the urgent need to meet timing limitations imposed by the review and funding cycle.

*Name of SEP:* Homocyst(E)inemia and Atherosclerosis.

*Date:* April 10-11, 1997.

*Time:* 8:00 p.m.

*Place:* Ramada, 1775 Rockville Pike, Rockville, Maryland 20852.

*Contact Person:* Eric H. Brown, Ph.D., Two Rockledge Center, Room 7204, 6701 Rockledge Drive, Bethesda, MD 20892-7924, (301) 435-0299.

*Purpose/Agenda:* To review and evaluate grant applications.

The meetings will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. (Catalog of Federal Domestic Assistance Programs Nos. 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; and 93.839, Blood Diseases and Resources Research, National Institutes of Health)

Dated: March 12, 1997.

LaVerne Y. Stringfield,  
*Committee Management Officer, NIH.*  
[FR Doc. 97-6630 Filed 3-14-97; 8:45 am]  
BILLING CODE 4140-01-M

### National Institute of General Medical Sciences; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following advisory committee meeting of the National Institute of General Medical Sciences:

*Committee Name:* Biomedical Research & Research Training Subcommittee-A.

*Date:* March 12, 1997.

*Time:* 8:00 a.m. until 6:00 p.m.

*Place:* Bethesda Holiday Inn, 8120 Wisconsin Avenue, Pennsylvania Room, Bethesda, Maryland 20814.

*Contact Person:* Carole H. Latker, Ph.D., Office of Scientific Review, Scientific Review Administrator, NIGMS, 45 Center Drive, Room 1AS-19G, Bethesda, MD 20892-6200, 301-594-2848.

*Purpose:* To review institutional research training grant applications.

This meeting will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5 U.S.C. Applications and the discussions of these could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

This notice is being published less than 15 days prior to the above meeting due to the urgent need to meet timing limitations imposed by the review and funding cycle.

(Catalog of Federal Domestic Assistance Programs Nos. 93.821, Biophysics and Physiological Sciences; 93.859, Pharmacological Sciences; 93.862, Genetics Research; 93.863, Cellular and Molecular Basis of Disease Research; 93.880, Minority Access Research Careers [MARC]; and 93.375, Minority Biomedical Research Support [MBRS])

Dated: March 12, 1997.

LaVerne Y. Stringfield,  
*Committee Management Officer, NIH.*  
[FR Doc. 97-6626 Filed 3-14-97; 8:45 am]  
BILLING CODE 4140-01-M

### National Institute of Arthritis and Musculoskeletal and Skin Diseases; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following National Institute of Arthritis and Musculoskeletal and Skin Diseases Special Emphasis Panel (SEP) meeting:

*Name of SEP:* Gene Therapy for Epidermolysis Bullosa.

*Date:* April 4, 1997.

*Time:* 8:30 a.m.-adjournment.

*Place:* Holiday Inn Bethesda, 8120 Wisconsin Avenue, Bethesda, Maryland 20814.